Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II multi-center, randomized-controlled study to evaluate the safety, clinical benefit, and anti-viral activity of Silmitasertib in patients hospitalized with COVID-19

Next Previous
Trial Profile

A phase II multi-center, randomized-controlled study to evaluate the safety, clinical benefit, and anti-viral activity of Silmitasertib in patients hospitalized with COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Silmitasertib (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Senhwa Biosciences

Most Recent Events

  • 30 Jun 2021 New trial record
  • 23 Jun 2021 According to a Senhwa Biosciences media release, the company has submitted an Investigational New Drug (IND) application to India's Central Drugs Standard Control Organization (CDSCO) to evaluate its investigational drug, Silmitasertib, for the treatment of COVID-19.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top